Life‑science investor Epidarex Capital closed a $145 million first close on its fourth fund to target overlooked UK and US research corridors and seed the next generation of platform and translational biotech companies. The fund positions Epidarex to chase early licensing or spinout opportunities and reflects ongoing VC appetite for deep‑science, early‑stage deals despite broader market caution.